Innovent and NeoCura to Test PD-1/mRNA Vaccine Combination for Cancer
publication date: Oct 28, 2021
Suzhou Innovent and Shenzhen NeoCura will test a combination of Innovent's PD-1, sintilimab, and NeoCura's individual neoantigen mRNA vaccine in patients with solid tumor cancers. NeoCura's NEO_PLIN2101, a mRNA vaccine encoded corresponding neoantigen, is synthesized in vitro and vaccinated into patients to activate tumor-specific T cells. The company believes its patient-based vaccine has better specificity and immunogenicity than other therapies. Innovent will conduct a China trial to assess the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the combination therapy. More details....
Stock Symbol: (HK: 01801)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.